In the past 24 months, Merck has made significant strides in expanding its oncology and immunology portfolios through strategic acquisitions, including the April 2023 purchase of Prometheus Biosciences for $10.8 billion, which bolsters its immunology pipeline with novel therapies for inflammatory bowel disease. Another key development was the January 2024 acquisition of Harpoon Therapeutics for approximately $680 million, enhancing Merck's capabilities in T-cell engager technologies for cancer treatment. In March 2024, the FDA approved Winrevair (sotatercept), a groundbreaking treatment for pulmonary arterial hypertension, marking a major milestone in Merck's cardiovascular disease efforts and potentially adding billions to its revenue stream. Additionally, Merck reported robust financial performance in 2023, with Keytruda sales reaching $25 billion, driven by expanded indications and global demand.

Merck & Co., Inc., known as MSD outside the United States and Canada, is a leading global biopharmaceutical company headquartered in Rahway, New Jersey, with a focus on developing innovative medicines, vaccines, and animal health products. Founded in 1891, the company currently employs over 70,000 people worldwide and generated approximately $60 billion in revenue in 2023, positioning it as a top player in oncology, vaccines, and infectious diseases. Merck's flagship product, Keytruda, an immunotherapy drug, has revolutionized cancer treatment and accounts for a significant portion of its sales. The company is committed to research and development, investing about $13.5 billion in R&D in 2023, and emphasizes sustainability and global health equity through initiatives like vaccine access programs in developing countries.

Merck leverages advanced technologies like artificial intelligence and machine learning in its drug discovery processes, partnering with companies such as Moderna for mRNA-based therapies, which gives it a competitive edge in personalized medicine. The company's IT and software applications include sophisticated data analytics platforms for clinical trials and supply chain management, integrating IoT for real-time monitoring in manufacturing. The biopharmaceutical industry is well-positioned for innovation, with Merck at the forefront through its digital health solutions and collaborations in AI-driven research. Merck has an above-average reputation in the industry for career development, offering robust training programs and mentorship, with competitive salaries for software engineers averaging around $120,000-$150,000 annually, according to industry benchmarks from sources like Glassdoor.

Merck faces challenges such as patent expirations for key drugs like Keytruda, expected around 2028, which could lead to increased generic competition and revenue pressure. Opportunities lie in expanding its pipeline through acquisitions and partnerships, particularly in emerging fields like gene therapy and rare diseases, capitalizing on its strong cash position. Threats include intense competition from rivals like Pfizer and Bristol-Myers Squibb, who are also advancing in immunotherapy, as well as regulatory hurdles and pricing pressures from governments worldwide. Additionally, supply chain disruptions and geopolitical tensions pose risks to global operations, while the company's heavy reliance on a few blockbuster drugs limits diversification.